Search | Clinical Trials Finder

Conditions: Kidney Transplantation
Interventions: CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Acute Stroke, Acute Ischemic Stroke, Ischemic Stroke, Hemorrhagic Stroke
Interventions: Serum and Urine measurement of cytokines.; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Parkinson Disease
Interventions: Aerobic exercise; Procedure
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 30 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Parkinson's Disease
Interventions: LUBIPROSTONE; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Houston, Texas

Conditions: Asthma
Interventions: AS MDI, Proventil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Winter Park, Florida • North Dartmouth, Massachusetts • St Louis, Missouri + 2 more

Conditions: Parkinson's Disease
Interventions: Capsaicin vapor, fog, Videofluoroscopic swallow evaluation, Nebulizer; Drug · Other · Radiation + 1 more
Lead sponsor: University of Florida; Other
Eligibility: 50 Years to 80 Years
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Convergence Insufficiency
Interventions: Active home-based computer vergence/accommodative therapy, Near target push-ups, Placebo home-based computer vergence/accommodative therapy, Placebo yoked prism flippers; Other · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 9 Years to 17 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Cranberry TWP, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Parkinson Disease
Interventions: INS-GSH, Matched Placebos; Drug
Lead sponsor: Gateway Institute for Brain Research; Industry
Eligibility: 30 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more

Conditions: Ulcerative Colitis
Interventions: RO7049665, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Advanced Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 30 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 23 more

Conditions: Sickle Cell Disease
Interventions: TAK-755, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more

Conditions: Healthy Volunteers
Interventions: MRT-6160, Placebo; Drug
Lead sponsor: Monte Rosa Therapeutics, Inc; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: High-risk Non-muscle Invasive Bladder Cancer
Interventions: Pembrolizumab, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 44
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more

Conditions: Overactive Bladder in Parkinson's Disease
Interventions: solifenacin succinate (VESIcare), placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 40 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia

Conditions: Lymphoma, T-Cell, Cutaneous
Interventions: placebo for SHAPE (SHP-141), SHAPE (SHP-141) 0.1% BID, SHAPE (SHP-141) 0.5% BID, SHAPE (SHP-141) 1.0% BID; Drug
Lead sponsor: TetraLogic Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Cleveland, Ohio + 2 more

Conditions: Multiple Myeloma
Interventions: Ramantamig, Tocilizumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Goodyear, Arizona • Beverly Hills, California • Irvine, California + 2 more

Conditions: Idiopathic Parkinson's Disease
Interventions: apomorphine infusion; Drug
Lead sponsor: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more

Conditions: Obesity
Interventions: ISIS-FGFR4RX, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Parkinson Disease
Interventions: Fasting, No Intervention; Other
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hemophilia A, Hemophilia B
Interventions: BAY86-6150, eptacog alfa [activated]; Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 62 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Sacramento, California • Chattanooga, Tennessee

Conditions: Generalized Anxiety Disorder
Interventions: PD 0332334, Paroxetine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 45
States / cities: Litchfield Park, Arizona • Costa Mesa, California • Pasadena, California + 37 more

Conditions: Parkinson's Disease (PD), Alzheimer's Disease (AD) and Related Disorders, Older Adults (60 - 85 Years Old)
Interventions: Complex Rhythmic Movement Sequences (CRMS) Sessions; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Generalized Anxiety Disorder
Interventions: PD 0332334, paroxetine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Birmingham, Alabama • Glendale, California • Orange, California + 22 more

Conditions: Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Interventions: TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more

Search by objective public record fields.

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

Cytokine Registry Database of Stroke Patients

Exercise Neuroprotection in Parkinson's Disease

Amitiza in Constipation Associated With PD (Parkinson's Disease)

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

Cough According to Stimulus Type in PD

Convergence Insufficiency Treatment Study (CITS)

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

First-in-human Study of MRT-6160 in Healthy Subjects

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Infusion of Apomorphine: Long-term Safety Study

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

Dance and Energy Expenditure Among Adults With Parkinson's

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

Moving Yourself in Space and Time: MYSTIC

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)